Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

CG Oncology (CGON) Cash & Equivalents: 2023-2024

Historic Cash & Equivalents for CG Oncology (CGON) over the last 2 years, with Dec 2024 value amounting to $257.1 million.

  • CG Oncology's Cash & Equivalents rose 3.99% to $45.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $45.1 million, marking a year-over-year increase of 3.99%. This contributed to the annual value of $257.1 million for FY2024, which is 3009.94% up from last year.
  • According to the latest figures from FY2024, CG Oncology's Cash & Equivalents is $257.1 million, which was up 3,009.94% from $8.3 million recorded in FY2023.
  • In the past 5 years, CG Oncology's Cash & Equivalents ranged from a high of $257.1 million in FY2024 and a low of $8.3 million during FY2023.
  • In the last 2 years, CG Oncology's Cash & Equivalents had a median value of $132.7 million in 2023 and averaged $132.7 million.
  • Data for CG Oncology's Cash & Equivalents shows a peak YoY spiked of 3,009.94% (in 2024) over the last 5 years.
  • Over the past 2 years, CG Oncology's Cash & Equivalents (Yearly) stood at $8.3 million in 2023, then soared by 3,009.94% to $257.1 million in 2024.